Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linezolid or Vancomycin Surgical Site Infection Prophylaxis
NCT05571722Phase 4Recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Nov 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of linezolid in surgical site infection (SSI) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Surgical Site Infection Rate at 30 days. Started Nov 2024; status: recruiting.
02
Drugs
linezolid
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05571722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571722.